Amarin Corporation plc appointed Aaron Berg, currently Amarins Executive Vice President and President of the U.S. Business, as Interim President. In addition, the board has appointed Oliver OConnor as a new independent Director of the company. Both appointments are effective 17 April 2023.

Mr. Berg joined Amarin in November 2012 and has more than 25 years of biopharmaceutical industry experience. Mr. Berg initially served as Amarins Vice President, Marketing and Managed Care. He was promoted to Senior Vice President, Marketing and Sales in February 2014, and to the position of Senior Vice President and Chief Commercial Officer in April 2018.

Before joining Amarin, Mr. Berg served as President and Chief Executive Officer for Essentialis Inc., a development stage pharmaceutical company where he led the company's work on triglyceride management. Prior to joining Essentialis, Mr. Berg served as Vice President of Marketing and Sales at Kos Pharmaceuticals (Kos), where he was instrumental in driving annual revenues approaching $1 billion. Mr. Berg worked at Kos until it was acquired by Abbott Laboratories in December 2006 for $3.7 billion.

Mr. OConnor brings more than 30 years of experience in government and policy, pharmaceutical industry, banking and finance experience to the Amarin Board. He currently serves as CEO of the Irish Pharmaceutical Healthcare Association and as a Board Member of the Irish Medicines Verification Organisation. Earlier in his career, Mr. OConnor served as an advisor to the Deputy Prime Minister, Minister for Enterprise, Trade and Employment and Minister for Health and Children in Ireland.

With the addition of Mr. OConnor, the Amarin Board of Directors now comprises 8 directors, including an Irish-domiciled Board member and all of whom are independent.